Investors of Telix Pharmaceuticals Invited to Join Class Action Lawsuit Following Substantial Losses

Investor Alert: Join the Telix Pharmaceuticals Class Action Lawsuit

Investors who have experienced significant losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) are presented with an important opportunity to engage in a class action lawsuit against the company. This movement is spearheaded by Robbins Geller Rudman & Dowd LLP, a well-known firm in the realm of securities litigation. The lawsuit aims to represent individuals who purchased or acquired Telix's publicly traded securities between February 21, 2025, and August 28, 2025.

Background of the Class Action Lawsuit

The class action, titled Thomas v. Telix Pharmaceuticals Ltd., is registered in the Southern District of Indiana under case number 25-cv-02299. It alleges that the company and certain executives breached the Securities Exchange Act of 1934. The claims suggest that there were misleading statements regarding the development of therapeutic candidates for prostate cancer and the reliability of the company's supply chain.

During the class period, Telix reportedly overstated its advancements in prostate cancer treatment and the operations of its supply chain partners. This misinformation led investors to believe in a flawed growth narrative, resulting in significant financial losses.

On July 22, 2025, the situation escalated when Telix disclosed that it had received a subpoena from the U.S. Securities and Exchange Commission (SEC). This subpoena was related to the company’s disclosures concerning the development of prostate cancer therapeutics. Following this news, the price of Telix's American Depositary Shares (ADSs) plummeted by over 13% in a short two-day trading window.

Further complicating matters, a statement issued on August 28, 2025, revealed that Telix had received a Complete Response Letter from the FDA regarding its Biologics License Application for TLX250-CDx. The FDA had pinpointed serious deficiencies linked to the Chemistry, Manufacturing, and Controls (CMC) package. Additionally, notice of deficiencies was issued to two third-party manufacturing partners, rendering them unable to facilitate operations until effective remediation was assured. As a result, Telix’s ADSs suffered another staggering decline of over 21% within two trading sessions.

The Lead Plaintiff Process

The Private Securities Litigation Reform Act of 1995 allows any individual who bought Telix's publicly traded securities during the defined class period to seek designation as the lead plaintiff in the class action. The lead plaintiff typically is the individual with the greatest financial stake in the case and can influence the direction of the lawsuit while representing the interests of all affected investors.

It is important to note that the ability to recover any potential future losses does not hinge on serving as the lead plaintiff. Investors can independently choose representation from an attorney or firm of their preference, granting them a say in the litigation’s progress.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP is one of the world’s foremost law firms dedicated to representing investors in cases of securities fraud and shareholder disputes. The firm consistently ranks at the top for securing monetary relief for investors and has successfully recovered over $2.5 billion in securities class action cases in 2024 alone. Their rigorous pursuit of justice has established them as leaders in this sector, and they have overseen some of the largest recoveries in securities litigation history.

Should you wish to participate in the Telix class action lawsuit or seek additional information, please contact attorneys J.C. Sanchez or Jennifer N. Caringal at Robbins Geller by calling 800-449-4900 or via email at [email protected]. The path to justice for investors begins with reclaiming the narrative surrounding Telix Pharmaceuticals.

For further details and updates regarding this class action lawsuit, ensure you follow all announcements from Robbins Geller and stay informed about your rights as an investor.